other material
confidence high
sentiment positive
materiality 0.60
Genprex granted Singapore patent for Reqorsa with anti-PD-1 antibodies through 2037
Genprex, Inc.
- Singapore Patent Office grants patent covering Reqorsa (quaratusugene ozeplasmid) in combo with anti-PD-1 antibodies until 2037.
- Patent expands on previously granted patents in U.S., Japan, Mexico, Russia, Australia, Chile, China, and Korea.
- Korean patent also claims Reqorsa with PD-L1 antibodies; Genprex plans similar filings in U.S., Brazil, Canada, China, Europe, Israel.
- Patent supports Acclaim-3 Phase 1/2 trial for ES-SCLC maintenance therapy combining Reqorsa with Tecentriq.